M+QuickMedCalc
Educational reference only. Not a diagnostic tool. See full disclaimer.
CardiologyTC/HDL Ratio

Total Cholesterol-to-HDL Ratio Calculator

Calculate the unitless total cholesterol-to-HDL-C ratio from one same-panel lipid profile, with exact arithmetic and current-guideline limitations.

Content updated: View sources

QuickMedCalc is developed and maintained by an independent developer. Medical content is not independently reviewed by a physician.

Formula and medical content are based on the references listed on this page. See sources, About, and Sources and Review Process.

Use the value from the same lipid panel and selected unit.

Use the value from the same lipid panel and selected unit.

About

This page calculates only total cholesterol ÷ HDL-C from one lipid panel and one clinical time point. The result is unitless arithmetic, not a directly measured lipoprotein or particle value, an individual ASCVD probability, a PREVENT input or output, or a universal treatment target. It does not calculate LDL-C, non-HDL-C, ApoB, ApoA-I, Lp(a), particle number, or another ratio, and it does not choose a drug, dose, test, or treatment. [7, 9]

Historical Framingham work described population associations between total cholesterol, HDL-C, and the ratio; Kinosian compared levels and ratios for historical prediction, and Ridker studied lipid measures and ratios in 15,632 initially healthy women followed for about 10 years. These are cohort or prediction findings for their study populations, not a modern personal probability or a causal estimate of changing a submitted ratio.[1, 2, 3]

Current laboratory and guideline pathways emphasize absolute LDL-C, non-HDL-C, triglycerides, Lp(a), ApoB, and complete risk information. PREVENT uses HDL-C and non-HDL-C as separate predictors rather than this quotient; PREVENT does not use the submitted TC/HDL-C ratio as an input or output. The 2026 dyslipidemia guideline does not define a universal TC/HDL-C treatment target. ADLM guidance notes that ratios have been studied but are not formally adopted as a routine calculated laboratory metric; its correction is listed separately.[5, 6, 7, 8, 9, 10]

Formula

TC/HDL-C ratio = total cholesterol ÷ HDL-C. Use positive same-panel values in the same selected concentration unit; the result is dimensionless.[1, 9]
200 mg/dL ÷ 50 mg/dL = 4.00; 5.2 mmol/L ÷ 1.3 mmol/L = 4.00. The same unit cancels in division; this page does not convert or mix units.[9, 11]
Total cholesterol must be greater than zero, HDL-C must be greater than zero, and HDL-C may not exceed total cholesterol. No ratio cutoff, risk percentage, PREVENT calculation, target, or treatment output is generated.

Interpretation

Same ratio, different absolute lipid values

Arithmetic examples only; not normal values, targets, or treatment comparisons.
Total cholesterolHDL-CTC/HDL-CNon-HDL-C
200 mg/dL50 mg/dL4.00150 mg/dL
120 mg/dL30 mg/dL4.0090 mg/dL

The ratios match while the absolute TC, HDL-C, and non-HDL-C values differ. A ratio cannot reconstruct TC or HDL-C and cannot infer LDL-C, triglycerides, ApoB, or Lp(a). [3, 9]

Historical evidence versus current role

Source-specific context; no row is a user-result classifier.
EvidenceWhat it contributesWhat it does not establish
Framingham 1992Historical observational association of lipid levels and ratios with CHD in a defined cohort.No modern personal probability, universal threshold, or causal treatment effect.
Kinosian 1994Historical comparison of cholesterol levels and ratios for prediction/discrimination.No current treatment target or universal cutoff.
Ridker 2005Association of ratios and other lipid measures with future events in a specific women’s cohort.No extrapolation to every sex, age, disease state, or treatment pathway.
Current laboratory/guideline roleAbsolute LDL-C, non-HDL-C, triglycerides, Lp(a), ApoB, and full risk pathways are used as appropriate.No universal TC/HDL-C treatment goal is assigned by this page.

The lower-is-better language found in some historical or consumer contexts is not a fixed risk ladder here. This page never compares a submitted ratio with a static threshold. [1, 2, 3, 7, 8]

PREVENT is a different model

PREVENT uses HDL-C and non-HDL-C as independent predictors in a multivariable equation. Non-HDL-C can be obtained as TC − HDL-C, but PREVENT is not the simple TC/HDL-C quotient. The same ratio can correspond to different non-HDL-C values, so it cannot produce the same PREVENT risk. This page lacks age, systolic blood pressure, eGFR, diabetes, smoking, and treatment variables and therefore cannot calculate a risk percentage. [5, 6]

What HDL-C association does and does not mean

Higher HDL-C is often associated with lower events in observational cohorts, but association is not proof that simply raising HDL-C causes protection. Voight’s Mendelian-randomisation study found that some genetic HDL-C increases did not lower myocardial-infarction risk. HDL-C concentration also does not describe every aspect of HDL function, and very high HDL-C is not unlimited protection. No U-shaped threshold or correction of the submitted ratio is performed. [3, 4]

Different measures are not interchangeable

Static measurement comparison; this runtime returns only TC/HDL-C.
MeasureInput or meaningCalculated here?
TC/HDL-CTotal cholesterol ÷ HDL-C; unitless arithmetic.Yes
Non-HDL-CTC − HDL-C; cholesterol concentration used in current pathways.No
LDL-C/HDL-CLDL-C divided by HDL-C; a different page and denominator context.No
ApoB/ApoA-IIndependent apolipoprotein measurements and a different ratio.No
Atherogenic coefficientOften non-HDL-C/HDL-C; related algebraically but a different named framework.No
LDL particle numberParticle-related laboratory measurement.No

The page does not recommend which measurement to order. Absolute lipid values, particle measurements, and the applicable clinical pathway answer different questions. [7, 9, 10]

Fasting, units, and special contexts

TC and HDL-C should come from the same panel and clinical time point. Routine lipid profiles can often be fasting or nonfasting, but high triglycerides, inherited lipid disorders, childhood, pregnancy, acute illness, diabetes, CKD, FH, chylomicronemia, type III dysbetalipoproteinemia, cholestatic disease/LpX, treatment changes, very low or very high HDL-C, and laboratory method differences may limit interpretation. This page does not collect fasting status, decide a repeat test, or create a special diagnostic pathway. [7, 9, 10, 11]

Both entries must use the same unit. A correct same-panel conversion from mg/dL to mmol/L should preserve the ratio mathematically, but this calculator intentionally does not convert or mix entries. Changing the selected unit clears both numbers to prevent silent reinterpretation.

What the result represents: what this calculator preserves and loses

The quotient preserves a relative relationship between two same-panel concentrations. It loses the absolute TC and HDL-C values, non-HDL-C, LDL-C, triglycerides, ApoB, Lp(a), particle number, fasting state, treatment state, and clinical history. For that reason, 200/50 and 120/30 both display 4.00 while describing different absolute lipid panels. [1, 3, 9]

Worked example and how the arithmetic is audited

  1. Read total cholesterol and HDL-C from one submitted panel.
  2. Confirm that both strings use the selected identical concentration unit.
  3. Require total cholesterol and HDL-C to be positive and HDL-C not to exceed total cholesterol.
  4. Divide at full precision, then format the unitless ratio to two decimal places.

The displayed number is an arithmetic audit, not a category, risk estimate, target, or treatment response.

Input units

Choose mg/dL or mmol/L once for the panel and enter both total cholesterol and HDL-C in that same unit. The calculator does not infer a missing unit or silently convert mixed entries.

Applicable population

This is a transparent arithmetic tool for people with a reported total cholesterol and HDL-C from the same lipid panel. It does not establish whether a ratio is appropriate for a child, pregnancy, acute illness, inherited dyslipidemia, or any other special clinical context.

Why same-panel values matter

Lipid concentrations can differ with time, laboratory method, acute illness, feeding, treatment, or a changing physiologic state. Mixing dates or panels creates a quotient that may describe no real specimen. Routine fasting is not required in every lipid workflow, but the page cannot decide when fasting or repeat testing is appropriate. [9, 11]

Historical ratio evidence without a threshold ladder

Castelli, Kinosian, and Ridker are useful for understanding why lipid ratios were studied, including their cohort associations and historical discrimination. Their populations, eras, outcomes, and models differ. They do not justify a universal 3.5, 4, 5, or 6 ladder, a sex-specific ideal, a personal event probability, or a treatment goal. [1, 2, 3]

Why the current pathway uses more than this ratio

Current laboratory guidance and the 2026 dyslipidemia guideline use absolute measures and complete risk pathways. The page does not infer LDL-C, non-HDL-C, ApoB, Lp(a), or a particle count from the ratio and does not select a medication or laboratory test. The ADLM correction is kept as a separate source rather than silently merged into the primary guidance. [7, 8, 9, 10]

HDL-C is a concentration, not a guarantee

Observationally higher HDL-C often travels with lower event rates, but HDL-C concentration cannot summarize HDL function or prove causality. Mendelian-randomisation results challenged the assumption that every genetically mediated HDL-C increase lowers myocardial-infarction risk. This page does not label very high HDL-C as protective, harmful, or U-shaped and does not alter the submitted quotient. [3, 4]

Interpretation limitations: what this page cannot determine

It cannot diagnose dyslipidemia, ASCVD, familial hypercholesterolemia, or another disease; calculate PREVENT or Framingham risk; set a personal goal; select a medicine, dose, test, or diet; or estimate the benefit of changing a lipid value. A clinician must interpret complete laboratory and clinical information when a decision is needed.

References

  1. Castelli WP, Anderson K, Wilson PWF, Levy D. Lipids and risk of coronary heart disease. The Framingham Study. Ann Epidemiol. 1992;2(1–2):23–28. PMID 1342260. DOI 10.1016/1047-2797(92)90033-M.
  2. Kinosian B, Glick H, Garland G. Cholesterol and coronary heart disease: predicting risks by levels and ratios. Ann Intern Med. 1994;121(9):641–647. PMID 7944071. DOI 10.7326/0003-4819-121-9-199411010-00002.
  3. Ridker PM, Rifai N, Cook NR, Bradwin G, Buring JE. Non-HDL cholesterol, apolipoproteins A-I and B100, standard lipid measures, lipid ratios, and CRP as risk factors for cardiovascular disease in women. JAMA. 2005;294(3):326–333. PMID 16030277. DOI 10.1001/jama.294.3.326.
  4. Voight BF, Peloso GM, Orho-Melander M, et al. Plasma HDL cholesterol and risk of myocardial infarction: a Mendelian randomisation study. Lancet. 2012;380(9841):572–580. PMID 22607825. PMCID PMC3419820. DOI 10.1016/S0140-6736(12)60312-2.
  5. Khan SS, Matsushita K, Sang Y, et al. Development and Validation of the American Heart Association's PREVENT Equations. Circulation. 2024;149(6):430–449. PMID 37947085. PMCID PMC10910659. DOI 10.1161/CIRCULATIONAHA.123.067626.
  6. Correction to: Development and Validation of the American Heart Association's PREVENT Equations. Circulation. 2024. PMID 38466792. DOI 10.1161/CIR.0000000000001230.
  7. Blumenthal RS, Morris PB, Gaudino M, et al. 2026 ACC/AHA/AACVPR/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Dyslipidemia. Circulation. 2026;153:e1154–e1276. PMID 41824552. DOI 10.1161/CIR.0000000000001423.
  8. Correction to: 2026 ACC/AHA/AACVPR/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Dyslipidemia. Circulation. 2026. PMID 42330109. DOI 10.1161/CIR.0000000000001457.
  9. Cao J, Donato L, El-Khoury JM, et al. ADLM Guidance Document on the Measurement and Reporting of Lipids and Lipoproteins. J Appl Lab Med. 2024;9(5):1040–1056. PMID 39225455. DOI 10.1093/jalm/jfae057.
  10. Correction to: ADLM Guidance Document on the Measurement and Reporting of Lipids and Lipoproteins. J Appl Lab Med. 2025. PMID 40172951. DOI 10.1093/jalm/jfaf021.
  11. Nordestgaard BG, Langsted A, Mora S, et al. Fasting is not routinely required for determination of a lipid profile. Eur Heart J. 2016;37:1944–1958. PMID 27122601. PMCID PMC4929379. DOI 10.1093/eurheartj/ehw152.

FAQ

Related Calculators

Non-HDL-C

Calculate non-HDL cholesterol from total cholesterol minus HDL-C from the same lipid panel, with unit-safe arithmetic and guideline-context limitations.

LDL/HDL Ratio

Calculate the unitless LDL-C-to-HDL-C ratio from one same-panel lipid profile, with method-aware arithmetic and current-guideline limitations.

ASCVD

Estimate 10-year and age-eligible 30-year risk of a first ASCVD event with the corrected AHA PREVENT base equations.

Disclaimer

Educational and informational reference only. Not intended to replace professional medical advice, diagnosis, treatment, or independent verification.